Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 199
Filter
Add more filters










Publication year range
1.
J Immunol ; 202(9): 2609-2615, 2019 05 01.
Article in English | MEDLINE | ID: mdl-30902899

ABSTRACT

Cholecystokinin (CCK) is a peptide hormone that functions in digestive organs and the CNS. We previously showed that CCK downregulates peripheral pruritus by suppressing degranulation of mast cells. In this study, we demonstrated that CCK octapeptide (CCK8) was constitutively expressed in the epidermis of normal skin, whereas its expression was lost in acanthotic lesions of psoriasis. In contrast, CCKA receptor (CCKAR), a high-affinity receptor for CCK, was constitutively expressed in the epidermis of psoriatic skin lesions. Expression of CCK was also reduced in skin lesions of an imiquimod (IMQ)-induced psoriatic mouse model. Notably, the expression level of CCK inversely correlated with the severity of epidermal inflammation, raising the possibility that CCK from epidermal keratinocytes suppresses the psoriatic inflammation. To verify this hypothesis, we investigated the effects of sulfated CCK octapeptide (CCK8S) on the development of IMQ-induced psoriatic inflammation. i.p. injection of CCK8S suppressed the IMQ-induced psoriatic inflammation accompanied by reduced mRNA expression of IL-17, IL-22, and IL-6 but not of IL-23. The suppressive effect of CCK8S was completely restored by administration of CCKAR antagonist. In vitro studies showed that exogenous CCK8S suppressed IL-6 production in CCKAR-expressing cultured human keratinocytes, and blocking the endogenous CCK signaling with CCKAR antagonist markedly enhanced IL-6 production. When keratinocytes were stimulated with IL-17, the expression of endogenous CCK was significantly decreased. These findings suggest that CCK physiologically functions as a negative regulator of keratinocyte-based inflammation in an autocrine or paracrine manner, although decreased CCK may pathologically contribute to continuous and aggravated skin lesions such as psoriasis.


Subject(s)
Cholecystokinin/immunology , Down-Regulation/immunology , Epidermis/immunology , Keratinocytes/immunology , Psoriasis/immunology , Signal Transduction/immunology , Animals , Autocrine Communication/drug effects , Autocrine Communication/immunology , Epidermis/pathology , Female , Humans , Imiquimod/pharmacology , Inflammation/immunology , Inflammation/pathology , Interleukin-17/immunology , Interleukin-6/immunology , Keratinocytes/pathology , Male , Mice , Oligopeptides/immunology , Oligopeptides/pharmacology , Paracrine Communication/drug effects , Paracrine Communication/immunology , Psoriasis/pathology
3.
Hippocampus ; 22(8): 1758-69, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22431345

ABSTRACT

The CA2 region of the hippocampus has distinctive properties and inputs and may be linked with the pathology of specific psychiatric and neurological disorders. It is, therefore, important to understand CA2 circuitry and its involvement in the circuitry of the hippocampus. Properties of CA2 basket cells have been reported. However, other classes of CA2 interneurones with cell bodies located in stratum pyramidale remained to be described. In this study, the unusual axonal arbors of a novel subclass of dendrite-preferring CA2 interneurones whose somata are located in the pyramidal cell layer was revealed following intracellular recordings and biocytin labeling. One to four apical dendrites emerged from the soma, branched in stratum radiatum (SR) forming a tuft, but rarely penetrated stratum lacunosum-moleculare (SLM). One or two basal dendrites branched close to the soma, the branches extended through stratum oriens (SO) and often reached the alveus. Unlike CA2 bistratified cells, the axons of these cells arborized almost exclusively in SR with few, if any, branches extending to stratum pyramidale (SP), SO, or SLM. These interneurones again, unlike bistratified cells, were immunonegative for parvalbumin and cholecystokinin. Electrophysiologically, they were similar to some CA2 basket and bistratified cells in that they presented a "sag" in response to hyperpolarizing current injections and displayed spike frequency adaptation. They targeted the apical dendrites of neighboring CA2 pyramidal cells and received inputs from them.


Subject(s)
CA2 Region, Hippocampal/cytology , Interneurons/cytology , Pyramidal Cells/cytology , Action Potentials/physiology , Animals , Axons/metabolism , CA2 Region, Hippocampal/metabolism , Cholecystokinin/immunology , Cholecystokinin/metabolism , Dendrites/metabolism , Humans , Immunohistochemistry , Interneurons/metabolism , Male , Parvalbumins/immunology , Parvalbumins/metabolism , Patch-Clamp Techniques/methods , Pyramidal Cells/metabolism , Rats , Rats, Wistar , Synapses
4.
Scand J Clin Lab Invest ; 72(2): 175-9, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22136177

ABSTRACT

Peptide hormones may occur in particularly low amounts in samples from small animals. Hence, in a rat microdialysis study conventional immunoassays were not sufficiently sensitive to measure gastrin in the dialysis samples. We therefore exploited the observation that antibodies raised against the homologous hormone cholecystokinin (CCK) occasionally bind gastrin peptides with significantly higher affinity than the proper ligand. The immunoassay thus established could detect 1.0 pmol/l in 15 µl microdialysate, which corresponds to 23 attomol gastrin. Such detection limit is five-fold lower than that obtained with the most avid conventional gastrin antibodies. The results may encourage similar approaches for other peptides using homologue-raised antibodies when supersensitivity is required.


Subject(s)
Antibodies/blood , Cholecystokinin/immunology , Gastrins/analysis , Amino Acid Sequence , Animals , Gastrins/chemistry , Gastrins/immunology , Limit of Detection , Microdialysis , Molecular Sequence Data , Rabbits , Radioimmunoassay
5.
Int J Oncol ; 38(3): 593-601, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21186400

ABSTRACT

Cholecystokinin (CCK) and gastrin stimulate growth of pancreatic cancer. Although down-regulation of gastrin inhibits growth of pancreatic cancer, the contribution of endogenous CCK to tumor growth is unknown. The purpose of this study was to evaluate the role of endogenous CCK on autocrine growth of pancreatic cancer. Pancreatic cancer cell lines were analyzed for CCK mRNA and peptide expression by real-time RT-PCR and radioimmunoassay, respectively. The effect of endogenous CCK on growth was evaluated by treating cancer cells with CCK neutralizing antibodies and by down-regulating CCK mRNA by RNAi. Wild-type pancreatic cancer cells expressed significantly lower CCK mRNA and peptide levels than gastrin. Neither treatment of pancreatic cancer cells with CCK antibodies nor the down-regulation of CCK mRNA and peptide by shRNAs altered growth in vitro or in vivo. Conversely, when gastrin mRNA expression was down-regulated, the same cells failed to produce tumors in spite of having sustained levels of endogenous CCK. Pancreatic cancer cells produce CCK and gastrin; however, the autocrine production of gastrin is more important for stimulating tumor growth.


Subject(s)
Adenocarcinoma/pathology , Cell Proliferation , Cholecystokinin/physiology , Pancreatic Neoplasms/pathology , Adenocarcinoma/genetics , Adenocarcinoma/metabolism , Animals , Antibodies, Neutralizing/pharmacology , Autocrine Communication/drug effects , Autocrine Communication/genetics , Autocrine Communication/physiology , Cell Line, Tumor , Cell Proliferation/drug effects , Cholecystokinin/genetics , Cholecystokinin/immunology , Cholecystokinin/metabolism , Gastrins/analysis , Gastrins/genetics , Gastrins/metabolism , Gastrins/pharmacology , Gene Expression Regulation, Neoplastic/drug effects , Humans , Male , Mice , Mice, Nude , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/metabolism , RNA, Messenger/analysis , RNA, Messenger/metabolism , RNA, Small Interfering/pharmacology , Tissue Distribution , Xenograft Model Antitumor Assays
6.
Cell Tissue Res ; 341(2): 289-97, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20582553

ABSTRACT

Cholecystokinin (CCK) is secreted by neuroendocrine cells comprising 0.1%-0.5% of the mucosal cells in the upper small intestine. Using CCK promoter-driven green fluorescent protein (GFP) expression in transgenic mice, we have applied immunofluorescence techniques to analyze the morphology of CCK cells. GFP and CCK colocalize in neuroendocrine cells with little aberrant GFP expression. CCK-containing cells are either flask- or spindle-shaped, and in some cells, we have found dendritic processes similar to pseudopods demonstrated for gut somatostatin-containing D cells. Most pseudopods are short, the longest process visualized extending across three cells. Pseudopods usually extend to adjacent cells but some weave between neighboring cells. Dual processes have also been observed. Three-dimensional reconstructions suggest that processes are not unidirectional and thus are unlikely to be involved in migration of CCK cells from the crypt up the villus. Abundant CCK immunostaining is present in the pseudopods, suggesting that they release CCK onto the target cell. In order to identify the type of cells being targeted, we have co-stained sections with antibodies to chromogranin A, trefoil factor-3, and sucrase-isomaltase. CCK cell processes almost exclusively extend to sucrase-isomaltase-positive enterocytes. Thus, CCK cells have cellular processes possibly involved in paracrine secretion.


Subject(s)
Cholecystokinin/analysis , Intestine, Small/cytology , Neuroendocrine Cells/cytology , Pseudopodia/ultrastructure , Animals , Cholecystokinin/immunology , Chromogranin A/immunology , Fluorescent Antibody Technique , Intestinal Mucosa/cytology , Intestinal Mucosa/metabolism , Intestine, Small/metabolism , Mice , Mice, Transgenic , Mucins/immunology , Neuroendocrine Cells/chemistry , Paracrine Communication/immunology , Pseudopodia/chemistry , Somatostatin/metabolism , Somatostatin-Secreting Cells/chemistry , Somatostatin-Secreting Cells/cytology , Sucrase-Isomaltase Complex/immunology , Trefoil Factor-3
7.
Tissue Cell ; 40(1): 51-60, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18028972

ABSTRACT

The distribution of cholecystokinin-like immunoreactivity was studied in the central nervous system of the heteropteran insect Triatoma infestans using high-sensitivity immunocytochemistry. In the protocerebrum, CCK-IR somata were observed in the anteromedial, anterolateral and posterior cell-body layers. The neuropils displayed different densities of immunoreactive neurites. Few immunoreactive somata were found in the optic lobe in both the medial and lateral soma rinds, as well as in the proximal optic lobe. Immunoreactive fibers were present in the medulla and lobula neuropils. The sensory deutocerebrum contained a higher number of immunopositive perikarya than the antennal mechanosensory and motor center. The antennal lobe glomeruli displayed a moderate density of immunoreactive fibers. With regard to the subesophageal ganglion, numerous CCK-IR somata were found close to the root of the mandibular nerve; others were present in the soma rind of the remaining neuromeres. CCK-IR perikarya were present in both thoracic ganglia, with the abdominal neuromeres containing the highest number of positive somata. The neuropils of both ganglia showed moderate densities of immunopositive processes. The distribution of CCK-LI in somata and neuropils of central nervous system of T. infestans is widespread suggesting that a CCK-like peptide may act mainly as a neuromodulator in the integration of information from distinct sensory receptors.


Subject(s)
Central Nervous System/chemistry , Cholecystokinin/analysis , Triatoma/chemistry , Animals , Central Nervous System/immunology , Cholecystokinin/immunology , Ganglia, Invertebrate/metabolism , Immunohistochemistry , Triatoma/cytology
8.
Neurochem Res ; 32(3): 395-9, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17268856

ABSTRACT

Active immunization against cholecystokinin fragments 31-33 (CCK-3) and 30-33 (CCK-4) results in long-lasting changes of albino rats' behavior. CCK-3 and CCK-4 covalently linked to antigen-carrier evokes the suppression of the anxiety, decreases some signs of depression-like behavior and changes the level of bioamines and their catabolites in striatum at least for two months after immunization. These data can provide a perspective approach to the problem of long term correction of behavior.


Subject(s)
Anxiety/immunology , Biogenic Amines/metabolism , Brain/metabolism , Cholecystokinin/immunology , Oligopeptides/immunology , Tetragastrin/immunology , Animals , Corpus Striatum/immunology , Corpus Striatum/metabolism , Immunization , Male , Rats , Rats, Wistar , Restraint, Physical , Stress, Psychological/immunology , Swimming
9.
Endocrine ; 32(3): 338-44, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18246452

ABSTRACT

This study was conducted to investigate the effects of active immunization against cholecystokinin 8 (CCK(8)) on the content of serum CCK, expression of CCK, and CCK receptor gene in pigs. The subjects for this experiment were 15 pigs divided into three groups (5 pigs per group). The treated groups were immunized with CCK(8) conjugated to human serum albumin (HSA). The control group was immunized with same dosage of HSA. The average daily gain of pig fed with 250 microg CCK was significantly increased (P < 0.05), compared with the control group (0 microg CCK). The content of CCK(8), insulin, and leptin in serum was significantly (P < 0.05) decreased and the titer of CCK(8) antibody was significantly (P < 0.05) increased in treated groups compared to the control group. The levels of CCK gene and CCK receptor gene expression in jejunum, pituitary, and pancreas of the treated groups were significantly (P < 0.05) lower than that of the control group. It is concluded that optimal active immunization against CCK(8) could increase the content of CCK antibody and suppress CCK gene and CCK receptor gene expressions and in result improve feed intake and growth performance of pigs.


Subject(s)
Cholecystokinin/blood , Cholecystokinin/genetics , Gene Expression Regulation/immunology , Peptide Fragments/immunology , Receptors, Cholecystokinin/genetics , Swine/growth & development , Vaccination , Animals , Antibodies/blood , Cholecystokinin/immunology , Eating/physiology , Humans , Insulin/blood , Leptin/blood , Peptide Fragments/blood , Serum Albumin/pharmacology , Swine/blood , Swine/immunology
10.
Exp Oncol ; 28(2): 136-40, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16837905

ABSTRACT

AIM: To study the therapeutic effect of recombinant plasmid pcDNA3.1/CCK containing porcine gene of cholecystokinin (CCK). METHODS: The confirmed fragments of porcine CCK cDNA were cloned into the pcDNA3.1 vector. Recombinant plasmid pcDNA3.1/CCK was injected into the muscles of Syrian golden hamsters. Before gene transfer, orthotopic tumor model and liver metastasis model of hamster pancreatic cancer have been established by injection of 1 x 10(6) PGHAM-1 cells into the pancreas and spleen of golden hamsters. Then the CCK expression in vivo and the tumor inhibiting effect were analyzed. RESULTS: Our data revealed that recombinant plasmid pcDNA3.1/CCK had long-term expression in hamsters and induced generation of specific antibody. Antibody level correlated with the number of inoculations. Compared to the control, significant reduction in tumor volume, decrease in number of liver metastasis and a remarkable enhancement of survival rate were detected. CONCLUSION: Intramuscular injection of recombinant plasmid pcDNA3.1/CCK has significant antitumor and antimetastatic effect in vivo.


Subject(s)
Cholecystokinin/genetics , Genetic Therapy , Liver Neoplasms/prevention & control , Pancreatic Neoplasms/therapy , Animals , Antibodies/blood , Apoptosis , Cell Proliferation , Cholecystokinin/immunology , Cricetinae , Female , Gene Expression , Injections , Liver Neoplasms/secondary , Muscle, Skeletal/chemistry , Pancreatic Neoplasms/pathology , Plasmids/administration & dosage , RNA, Messenger/analysis , Swine , Xenograft Model Antitumor Assays
11.
Gut ; 55(4): 492-7, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16299028

ABSTRACT

BACKGROUND AND AIMS: Gastrointestinal inflammation reduces food intake but the biological mechanisms explaining suppressed feeding during inflammation are unknown. We have used a model of upper gut infection (Trichinella spiralis in the mouse) to study the effect of inflammation on food intake, and explored the role of a key enteroendocrine cell (EEC) in the regulation of feeding by the immune response. METHODS: Food intake of NIH mice infected with the intestinal nematode Trichinella spiralis was measured. Duodenal cholecystokinin (CCK) cells were counted. Plasma CCK was measured. Infected mice were treated with a specific CCK1 receptor antagonist, and food intake reassessed. The influence of the immune response on food intake and CCK was mechanistically examined by treating mice with CD4 or mast cell neutralising antibodies. The role of the T helper 2 response was further explored in mice genetically deficient for interleukin (IL)-4, IL-13, or IL-4Ralpha (receptor alpha subunit). RESULTS: Food intake of infected mice was significantly reduced at the temporal peak of intestinal inflammation. CCK expressing EEC were upregulated in infected mice, and plasma CCK levels were increased. A CCK1 receptor antagonist restored the food intake of infected mice to a significant degree. Furthermore, suppression of food intake was completely abolished in the absence of CD4+ T lymphocytes or IL-4Ralpha. CONCLUSIONS: The data show for the first time that intestinal inflammation results in reduced food intake due to upregulation of CCK. Moreover, following infection, food intake and CCK expressing cells are under the specific control of CD4+ T-cells, via release of IL-4 and IL-13.


Subject(s)
Eating/immunology , Enteroendocrine Cells/immunology , Feeding and Eating Disorders/immunology , Th2 Cells/immunology , Animals , Cell Count , Cholecystokinin/immunology , Cytokines/immunology , Disease Models, Animal , Duodenum/cytology , Duodenum/immunology , Feeding and Eating Disorders/parasitology , Immunohistochemistry/methods , Interleukins/immunology , Intestine, Small/immunology , Mast Cells/immunology , Mice , Mice, Inbred BALB C , Mice, Inbred Strains , Receptors, Cholecystokinin/antagonists & inhibitors , Trichinella spiralis/immunology , Trichinellosis/immunology
12.
J Pept Sci ; 12(5): 311-20, 2006 May.
Article in English | MEDLINE | ID: mdl-16245263

ABSTRACT

Metoclopramide, a prokinetic drug, is widely used to treat vomiting and nausea. Delayed gastric emptying and continual stress are considered important factors, among others, that induce nausea and vomiting. One gastrointestinal motility regulatory factor has been assumed to be the induction of changes in the levels of peptides such as gastrin, somatostatin, motilin, and cholecystokinin (CCK) in plasma. In contrast, adrenocorticotropic hormone (ACTH) and cortisol are used as indicators of stress. Here, we studied the effects of metoclopramide on human plasma gastrin-, somatostatin-, motilin-, and CCK-like immunoreactive substances (ISs) and ACTH-IS and cortisol under stress conditions using repetitive blood sampling in healthy subjects. Metoclopramide hydrochloride at a dose of 30 mg or placebo was orally administered to five healthy male volunteers. Blood samples were taken before and 20, 40, 60, 90, 120, 180, and 240 min after administration, subject to extracting procedures, and submitted to a highly sensitive enzyme immunoassay system. A single administration of metoclopramide caused significant increases in plasma somatostatin-IS levels compared with the placebo. Metoclopramide significantly decreased plasma gastrin- and suppressed ACTH-IS and cortisol levels compared with the placebo. We hypothesize that metoclopramide might have an accelerating gastric-emptying effect and a modulatory effect on the hypothalamo-pituitary-adrenal (HPA) axis and the autonomic nervous function. These effects might be beneficial in stress-related diseases, which suggest that this medicine has clinicopharmacological activities.


Subject(s)
Cholecystokinin/blood , Gastrointestinal Hormones/blood , Immunoenzyme Techniques/methods , Metoclopramide/pharmacology , Stress, Physiological/blood , Administration, Oral , Adrenocorticotropic Hormone/blood , Adrenocorticotropic Hormone/immunology , Adult , Cholecystokinin/drug effects , Cholecystokinin/immunology , Circadian Rhythm , Domperidone/administration & dosage , Domperidone/pharmacology , Dopamine Antagonists/administration & dosage , Dopamine Antagonists/pharmacology , Gastrins/blood , Gastrins/drug effects , Humans , Hydrocortisone/blood , Immunoenzyme Techniques/standards , Male , Metoclopramide/administration & dosage , Metoclopramide/blood , Motilin/blood , Motilin/drug effects , Reference Standards , Somatostatin/blood , Stress, Physiological/physiopathology , Time Factors
13.
Am J Physiol Gastrointest Liver Physiol ; 287(2): G326-33, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15064233

ABSTRACT

Nonsulfated CCK(58) [CCK(58)(ns)] has not been considered to be of biological importance because CCK(58)(ns) binds poorly to the CCK(A) receptor and has only been identified once in intestinal extracts. In this work, a radioimmunoassay specific for the COOH-terminal region of gastrin and CCK (antibody 5135) was used to monitor the purification of CCK molecular forms from canine intestinal extracts. A minor immunoreactive peak was associated with a major absorbance peak during an ion-exchange, HPLC step. Characterization of this minor immunoreactive peak demonstrated that it was CCK(58)(ns). CCK(58)(ns) is 14% as immunoreactive as sulfated CCK(8) [CCK(8)(s)]. Amino acid analysis demonstrated that CCK(58)(ns) was present at 50% the amount of CCK(58)(s). In addition, we found that CCK(58)(ns) does not potently displace an (125)I-labeled CCK(10) analog from the CCK(A) receptor in mouse pancreatic membranes and does not stimulate amylase release from isolated pancreatic acini, or stimulate pancreatic secretion in an anesthetized rat model. By contrast, CCK(58)(ns) does bind to CCK(B) receptors and stimulates gastric acid secretion via this receptor. The presence of CCK(58)(ns) and its ability to selectively stimulate the CCK(B) receptor without stimulation of the CCK(A) receptor suggest that CCK(58)(ns) may have unique physiological properties, especially tissues where the nonsulfated peptide can act as a paracrine or neurocrine agent.


Subject(s)
Cholecystokinin/isolation & purification , Cholecystokinin/physiology , Intestines/chemistry , Sincalide/analogs & derivatives , Amino Acids/analysis , Amylases/metabolism , Animals , Brain/metabolism , Cholecystokinin/chemistry , Cholecystokinin/immunology , Cholecystokinin/pharmacology , Dogs , Gastric Acid/metabolism , In Vitro Techniques , Male , Mice , Pancreas/drug effects , Pancreas/metabolism , Radioimmunoassay , Rats , Rats, Sprague-Dawley , Receptor, Cholecystokinin A/metabolism , Receptor, Cholecystokinin B/metabolism , Sincalide/pharmacology
14.
Bull Exp Biol Med ; 135 Suppl 7: 85-7, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12949661

ABSTRACT

Ultralow doses of antibodies to phenobarbital and their mixture (1:1) with ultralow doses of antibodies to cholecystokinin reduced the severity of structural and metabolic disturbances in the liver of rats with acute CCl4-induced hepatitis. The mixture of antibodies had no effect on the course of CCl4-induced hepatitis.


Subject(s)
Antibodies/pharmacology , Chemical and Drug Induced Liver Injury , Hepatitis, Chronic , Liver/drug effects , Materia Medica/pharmacology , Animals , Chemical and Drug Induced Liver Injury/drug therapy , Cholecystokinin/immunology , Dose-Response Relationship, Drug , Hepatitis, Chronic/drug therapy , Liver/metabolism , Liver/pathology , Phenobarbital/immunology , Rats , Rats, Wistar
15.
Bull Exp Biol Med ; 135 Suppl 7: 88-90, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12949662

ABSTRACT

Ultralow doses of antibodies to cholecystokinin prevented hepatocyte death, delayed the formation of the connective tissue, and normalized plasma of liver enzyme in rats with experimental acute and chronic toxic hepatitis.


Subject(s)
Antibodies/pharmacology , Cholecystokinin/immunology , Liver/drug effects , Animals , Chemical and Drug Induced Liver Injury/drug therapy , Hepatitis, Chronic/drug therapy , Hepatitis, Chronic/metabolism , Liver/metabolism , Liver/pathology , Rats , Rats, Wistar
16.
Am J Physiol Regul Integr Comp Physiol ; 284(1): R66-75, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12388446

ABSTRACT

Type A CCK receptor (CCKAR) antagonists differing in blood-brain barrier permeability [devazepide penetrates; the dicyclohexylammonium salt of Nalpha-3-quinolinoyl-d-Glu-N,N-dipentylamide (A-70104) does not] were used to test the hypothesis that duodenal nutrient-induced inhibition of gastric emptying is mediated by CCKARs located peripheral to the blood-brain barrier. Rats received A-70104 (700 or 3,000 nmol. kg(-1). h(-1) iv) or devazepide (2.5 micromol/kg iv) and either a 15-min intravenous infusion of CCK-8 (3 nmol. kg(-1). h(-1)) or duodenal infusion of casein, peptone, Intralipid, or maltose. Gastric emptying of saline was measured during the last 5 min of each infusion. A-70104 and devazepide abolished the gastric emptying response to a maximal inhibitory dose of CCK-8. Each of the macronutrients inhibited gastric emptying. A-70104 and devazepide attenuated inhibitory responses to each macronutrient. Intravenous injection of a CCK antibody to immunoneutralize circulating CCK had no effect on peptone or Intralipid-induced responses. Thus endogenous CCK appears to act in part by a paracrine or neurocrine mechanism at CCKARs peripheral to the blood-brain barrier to inhibit gastric emptying.


Subject(s)
Cholecystokinin/pharmacology , Gastric Emptying/drug effects , Peptide Fragments/pharmacology , Receptors, Cholecystokinin/antagonists & inhibitors , Animals , Antibodies/immunology , Antibodies/pharmacology , Caseins/administration & dosage , Caseins/pharmacology , Cholecystokinin/antagonists & inhibitors , Cholecystokinin/immunology , Cholecystokinin/metabolism , Devazepide/pharmacology , Drug Administration Routes , Fat Emulsions, Intravenous/administration & dosage , Fat Emulsions, Intravenous/pharmacology , Hormone Antagonists/pharmacology , Male , Maltose/administration & dosage , Maltose/pharmacology , Peptide Fragments/antagonists & inhibitors , Peptide Fragments/immunology , Peptide Fragments/metabolism , Peptones/administration & dosage , Peptones/pharmacology , Quinolines/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Cholecystokinin/metabolism
17.
Hippocampus ; 12(2): 119-36, 2002.
Article in English | MEDLINE | ID: mdl-12000113

ABSTRACT

In the rat hippocampal formation, application of mu opioid receptor (MOR) agonists disinhibits principal cells, promoting excitation-dependent processes such as epileptogenesis and long-term potentiation. However, the precise location of MORs in particular inhibitory circuits, has not been determined, and the roles of MORs in endogenous functioning are unclear. To address these issues, the distribution of MOR-like immunoreactivity (-li) was examined in several populations of inhibitory hippocampal neurons in the CA1 region using light and electron microscopy. We found that MOR-li was present in many parvalbumin-containing basket cells, but absent from cholecystokinin-labeled basket cells. MOR-li was also commonly in interneurons containing somatostatin-li or neuropeptide Y-li that resembled the "oriens-lacunosum-moleculare" (O-LM) interneurons innervating pyramidal cell distal dendrites. Finally, MOR-li was in some vasoactive intestinal peptide- or calretinin-containing profiles resembling interneurons that primarily innervate other interneurons. These findings indicate that MOR-containing neurons form a neurochemically and functionally heterogeneous subset of hippocampal GABAergic neurons. MORs are most frequently on interneurons that are specialized to inhibit pyramidal cells, and are on a limited number of interneurons that target other interneurons. Moreover, the distribution of MORs to different neuronal types in several laminae, some relatively far from endogenous opioids, suggests normal functional roles that are different from the actions seen with exogenous agonists such as morphine.


Subject(s)
Hippocampus/chemistry , Hippocampus/cytology , Interneurons/chemistry , Receptors, Opioid, mu/analysis , Animals , Antibodies , Calbindin 2 , Cholecystokinin/analysis , Cholecystokinin/immunology , Enkephalins/analysis , Enkephalins/immunology , Interneurons/ultrastructure , Male , Microscopy, Electron , Neuropeptide Y/analysis , Neuropeptide Y/immunology , Parvalbumins/analysis , Parvalbumins/immunology , Rats , Rats, Sprague-Dawley , Receptors, Opioid, mu/immunology , S100 Calcium Binding Protein G/analysis , S100 Calcium Binding Protein G/immunology , Somatostatin/analysis , Somatostatin/immunology , Vasoactive Intestinal Peptide/analysis , Vasoactive Intestinal Peptide/immunology
18.
Neuroscience ; 107(4): 641-52, 2001.
Article in English | MEDLINE | ID: mdl-11720787

ABSTRACT

The neuronal localization of the CB1 cannabinoid receptor in the rat basolateral amygdala was studied using peroxidase and fluorescence immunohistochemical techniques. All nuclei of the basolateral amygdala contained a large number of lightly stained pyramidal neurons and a small number of more intensely stained non-pyramidal neurons. Most of the latter cells had medium-sized to large multipolar somata and three to four aspiny dendrites, but some exhibited smaller oval somata. The axon initial segments of some of these non-pyramidal neurons exhibited large swollen varicosities in colchicine-injected animals, suggesting that much of the CB1 receptor protein is transported down the axons of these cells. Double-labeling studies using immunofluorescence histochemistry combined with confocal laser scanning microscopy revealed that the great majority of non-pyramidal neurons with CB1 receptor immunoreactivity belonged to a cholecystokinin-containing subpopulation. Whereas none of the other subpopulations of non-pyramidal neurons (exhibiting immunoreactivity for calretinin, parvalbumin, or somatostatin) expressed high levels of CB1 receptor immunoreactivity, a small percentage of these cells exhibited low levels of immunoreactivity. The results indicate that cannabinoids may modulate the activity of pyramidal projection neurons as well as a subpopulation of cholecystokinin-containing non-pyramidal neurons in the basolateral amygdala. Previous studies indicate that most of the latter are inhibitory interneurons that utilize GABA as a neurotransmitter. The intense staining of the cholecystokinin-containing interneurons and the evidence that large amounts of CB1 receptor protein are transported down the axons of these cells suggests that, as in the hippocampus, cannabinoids may inhibit the release of GABA from the axon terminals of these neurons.


Subject(s)
Amygdala/chemistry , Cholecystokinin/analysis , Interneurons/chemistry , Receptors, Drug/analysis , Amygdala/cytology , Animals , Antibody Specificity , Cholecystokinin/immunology , Fluorescent Antibody Technique , Immunoenzyme Techniques , Male , Microscopy, Confocal , Rats , Rats, Sprague-Dawley , Receptors, Cannabinoid , Receptors, Drug/immunology
19.
Biol Res Nurs ; 1(4): 287-98, 2000 Apr.
Article in English | MEDLINE | ID: mdl-11232207

ABSTRACT

Anorexia during infection is thought to be mediated by immunoregulatory cytokines such as interleukins 1 and 6 and tumor necrosis factor. This article reviews the potential mechanisms of action by which these cytokines are thought to suppress food intake during infection and examines the proposition that blocking of cytokine activity might be one approach to improving food intake of the infected host.


Subject(s)
Anorexia/etiology , Anorexia/therapy , Cytokines/immunology , Infections/complications , Infections/immunology , Acute-Phase Reaction/immunology , Animals , Cholecystokinin/immunology , Dinoprostone/immunology , Disease Models, Animal , Eating/immunology , Fever/microbiology , Gastroparesis/microbiology , Humans , Infections/physiopathology , Inflammation Mediators/immunology , Leptin/immunology , Vagus Nerve/physiopathology
20.
Digestion ; 60 Suppl 1: 61-3, 1999.
Article in English | MEDLINE | ID: mdl-10026434

ABSTRACT

Evidence based on animal studies suggests that cholecystokinin (CCK) is involved in the induction and development of acute experimental pancreatitis. However, the results obtained with CCK or CCKA receptor antagonists in different species (rats, mice) and different models of acute pancreatitis (cerulein pancreatitis, hemorrhagic pancreatitis induced by choline-deficient, ethionine-supplemented diet, arginine-induced pancreatitis, sodium taurocholate-induced pancreatitis) produced variable results. The route of administration, the specificity and potency of compounds and the design of the study are predictive for the outcome. Based on the available information, CCK appears to play a contributory role in the development of acute experimental pancreatitis in mice and rats. No conclusions can be drawn from these results with respect to the human disease.


Subject(s)
Cholecystokinin/physiology , Pancreatitis/etiology , Receptors, Cholecystokinin/physiology , Acute Disease , Animals , Cholecystokinin/immunology , Disease Models, Animal , Humans , Mice , Pancreatitis/immunology , Rats , Receptors, Cholecystokinin/antagonists & inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL
...